Next Wave in Immune Therapeutics - Partnering Meetings with Johnson & Johnson Innovation
Opens Jul 9 2020 12:00 AM (PDT)
Deadline Dec 31 2020 11:59 PM (PST)
Description

If you are active in the specific areas of interest for Johnson & Johnson Innovation in immunology below, we highly recommend you request a 1:1 meeting with us to discuss potential collaboration opportunities.

If you have any questions please send them to Cosmin Popa (cpopa2@its.jnj.com).

Immune Pillars & Pathways:

Adaptive immunity

  • Promote negative regulation
  • Dampen lymphocyte activation

Innate Immunity

  • Promote immune homeostasis through mechanisms that dampen activation 
  • Enhance negative regulatory mechanisms

Tissue Inflammation

  • Promote barrier function and tissue-protective homeostatic mechanisms
  • Dampen tissue-driven amplification of inflammation

IL-23 Pathway

  • Novel approaches to target the IL-23 pathway

Disease Areas:

Gastroenterology

  • Crohn’s disease and ulcerative colitis
  • Refractory celiac disease

Immuno-Dermatology

  • Psoriasis
  • Atopic dermatitis
  • Hidradenitis suppurativa; palmoplantar pustulosis; (+ other)

Rheumatology

  • Rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis
  • Systemic lupus erythematosus; lupus nephritis 
  • Sjögren's syndrome; scleroderma (+other)

Next Wave in Immune Therapeutics - Partnering Meetings with Johnson & Johnson Innovation


If you are active in the specific areas of interest for Johnson & Johnson Innovation in immunology below, we highly recommend you request a 1:1 meeting with us to discuss potential collaboration opportunities.

If you have any questions please send them to Cosmin Popa (cpopa2@its.jnj.com).

Immune Pillars & Pathways:

Adaptive immunity

  • Promote negative regulation
  • Dampen lymphocyte activation

Innate Immunity

  • Promote immune homeostasis through mechanisms that dampen activation 
  • Enhance negative regulatory mechanisms

Tissue Inflammation

  • Promote barrier function and tissue-protective homeostatic mechanisms
  • Dampen tissue-driven amplification of inflammation

IL-23 Pathway

  • Novel approaches to target the IL-23 pathway

Disease Areas:

Gastroenterology

  • Crohn’s disease and ulcerative colitis
  • Refractory celiac disease

Immuno-Dermatology

  • Psoriasis
  • Atopic dermatitis
  • Hidradenitis suppurativa; palmoplantar pustulosis; (+ other)

Rheumatology

  • Rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis
  • Systemic lupus erythematosus; lupus nephritis 
  • Sjögren's syndrome; scleroderma (+other)
Opens
Jul 9 2020 12:00 AM (PDT)
Deadline
Dec 31 2020 11:59 PM (PST)